Anti-phospolipid Antibodies in Lyme Borreliosis

Launched by UNIVERSITY MEDICAL CENTRE LJUBLJANA · Apr 14, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating the levels of specific antibodies in people with Lyme borreliosis, a disease caused by a bacteria spread through tick bites. The researchers want to understand how these antibodies might be linked to the different symptoms of Lyme disease, such as skin rashes, joint pain, or neurological issues. The study will involve 150 patients who have clear cases of Lyme borreliosis, as well as 50 individuals with unclear symptoms who still test positive for Lyme, and 40 healthy blood donors for comparison.

To be eligible for this trial, participants should have a confirmed diagnosis of Lyme borreliosis based on specific medical guidelines. However, individuals with certain conditions like autoimmune diseases or those who are pregnant will not be included. Participants will provide blood samples at various points, before and after treatment, to help the researchers measure the levels of the antibodies being studied. This trial aims to shed light on Lyme disease and may help improve future diagnosis and treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fulfillment of clinical case definition criteria for European Lyme borreliosis (doi: 10.1111/j.1469-0691.2010.03175.x.).
• Exclusion Criteria:
• • Autoimmune diseases, acute myocardial infarction, acute deep vein thrombosis, pregnancy, syphilis.